JPRN-jRCT2080221766未知2 期
A phase 2, multicenter, open-label, single-arm study of ARQ 197 plus erlotinib in patient with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer
Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 40 人开始时间: 2012年4月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Key Inclusion Criteria:
- •- Histologically or cytologically confirmed surgically unresectable locally advanced or metastatic (stage IIIB/IV) NSCLC with EGFR activating mutation.
- •- Measurable disease and documented disease progression following the first and immediate EGFR-TKI monotherapy.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •- Adequate organ function
排除标准
- •Key Exclusion Criteria:
- •- Prior therapy with a c-Met inhibitor.
- •- Any systemic anti-tumor treatment for NSCLC within 7 days prior to randomization.
- •- Major surgical procedure within 4 weeks prior to randomization
- •- Known symptomatic brain metastases.
研究者
相似试验
已完成
2 期
Valemetostat Tosylate (DS-3201b) Phase 2 study in relapsed or refractory adult T-cell leukemia/lymphomaAdult T-cell leukemia/lymphoma: ATJPRN-jRCT2080224880DAIICHI SANKYO Co.,Ltd.25
招募中
1 期
A study to evaluate safety and efficacy of SOT101 in combination with pembrolizumab in patients with selected advanced/refractory solid tumorsEUCTR2021-005774-25-BESOTIO Biotech AG320
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of SOT101 in combination with cetuximab in patients with a specific subtype of colon and/or rectum cancerRAS wild-type colorectal cancerEUCTR2022-001527-32-BESOTIO Biotech AG52
进行中（未招募）
1 期
A study to evaluate safety and efficacy of SOT101 in combination with pembrolizumab in patients with selected advanced/refractory solid tumorsEUCTR2021-005774-25-PLSOTIO Biotech AG320
进行中（未招募）
1 期
A study to evaluate safety and efficacy of SOT101 in combination with pembrolizumab in patients with selected advanced/refractory solid tumorsadvanced/refractory solid tumorsMedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864MedDRA version: 24.1Level: LLTClassification code 10085908Term: Cutaneous squamous cell carcinomaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 100000004864EUCTR2021-005774-25-CZSOTIO Biotech AG320